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Abstract
Introduction:  We present the case of a patient with colon cancer who, while receiving
bevacizumab, developed sinusoidal obstruction syndrome (veno-occlusive disease) (SOSVOD).
Certain antitumour agents such as 6-mercaptopurine and 6-thioguanine have also been reported
to initiate hepatic SOSVOD in isolated cases. There have been no reports so far correlating
bevacizumab with SOSVOD.
Case presentation: A 77-year-old man was being treated with oxaliplatin and a modified de
Gramont regimen of 5-fluorouracil for metastatic colon cancer. Bevacizumab (7.5 mg/kg) was
added from the seventh cycle onwards. Protracted neutropenia and thrombocytopenia led to
discontinuation of oxaliplatin after the ninth cycle. A computed tomography scan showed complete
response and bevacizumab was continued for another 3 months, after which time the patient
developed right hypochondrial pain, transudative ascites, splenomegaly and abnormal liver function
tests. Upper gastrointestinal endoscopy showed oesophageal varices. Liver biopsy showed features
considered to be consistent with SOSVOD. Bevacizumab was stopped and a policy of watchful
waiting was adopted. He tolerated the acute damage to his liver and subsequently the ascites
resolved and liver function tests normalised.
Conclusion: We need to be aware that bevacizumab can cause sinusoidal obstruction syndrome
(veno-occlusive disease) and that the occurrence of ascites should not be attributed to progressive
disease without appropriate evaluation.
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Introduction
Severe sinusoidal obstruction syndrome (veno-occlusive
disease) (SOSVOD) represents a life-threatening compli-
cation of dose-intensive chemotherapy. Conventional
doses of certain antitumour agents such as 6-mercaptopu-
rine and 6-thioguanine have been reported to initiate
hepatic SOSVOD in isolated cases [1]. We present the first
case of a patient with colon cancer who, while receiving
bevacizumab, developed SOSVOD.
Case presentation
A 77-year-old man presented with rectal bleeding in
December 1998 due to carcinoma of the ascending colon
and subsequently underwent right hemicolectomy, The
tumour was staged as Dukes B. No adjuvant chemother-
apy was given at that time. In August 1999 he developed
disease recurrence in the liver (Figure 1a) and was treated
with 12 cycles of oxaliplatin and a modified de Gramont
regimen of 5-fluorouracil (OxMdg) with a good response
(Figure 1b). In October 2000 he underwent left hepatic
trisectionectomy, involving resection of hepatic segments
2, 3, 4, 5 and 8, and liver remnant metastasectomies of
segments 1, 6 and 7, along with revision of the right hemi-
colectomy due to local recurrence. There was no evidence
of chemotherapy-associated steatohepatitis in the hepate-
ctomy specimen. His liver enzymes and synthetic function
returned to normal after this.
He developed further extensive nodal recurrence both
supra- and infra-diaphragmatically in November 2004
and was rechallenged with OxMdg. Bevacizumab at a dose
of 7.5 mg/kg (675 mg) was added to the regimen from the
seventh cycle onwards and was given every 4 weeks. Pro-
tracted neutropenia and thrombocytopenia led to discon-
tinuation of oxaliplatin after the ninth cycle. His liver
function tests at the time of discontinuing oxaliplatin
CT scans Figure 1
CT scans. (a) Liver metastasis (long arrow). (b) Response with reduction in the size of the liver metastasis (long arrow). (c) 
Development of varices at the lower oesophagus (long arrow). (d) Splenomegaly (long arrow) and ascites (short arrow).Journal of Medical Case Reports 2008, 2:227 http://www.jmedicalcasereports.com/content/2/1/227
Page 3 of 4
(page number not for citation purposes)
were bilirubin 17 μmol/l, alkaline phosphatase 134 IU/l,
alanine aminotransferase 87 IU/l and albumin 30 g/l. 5-
fluorouracil was stopped after cycle 11 due to a computed
tomography (CT) scan in July 2005 showing a complete
response.
Maintenance bevacizumab (7.5 mg/kg every 4 weeks) was
continued as a single agent. In September 2005 he devel-
oped right hypochondrial pain and liver function tests
showed raised bilirubin 26 μmol/l, alkaline phosphatase
217 IU/l, alanine aminotransferase 99 IU/l and albumin
30 g/l along with persistent thrombocytopenia (<100 ×
109/l). He was not on any other medications which would
significantly alter the liver function tests. CT scan showed
oesophageal varices (Figure 1c), new ascites and splenom-
egaly (Figure 1d). The ascitic fluid was transudate with no
evidence of malignant cells. Upper gastrointestinal endos-
copy showed oesophageal varices, a Barrett's oesophagus
and portal gastropathy. These findings were all consistent
with an intrahepatic cause of portal hypertension. Liver
biopsy showed Kupffer cell hyperplasia (Figure 2a) and
pericellular fibrosis (Figure 2b) with a predominantly cen-
trilobular distribution, but no definite occluded vessels
were seen. There was no evidence of cirrhosis. These fea-
tures were considered to be consistent with SOSVOD.
Subsequently, bevacizumab was stopped in October 2005
and a policy of watchful waiting was adopted. The patient
recovered from the acute damage to his liver and subse-
quently the ascites resolved and liver function tests nor-
malized. As of September 2007 the patient remains in
complete remission but with persistent thrombocytope-
nia, splenomegaly and gastroesophageal junction varices.
Discussion
There have been no reports so far correlating bevacizumab
with SOSVOD. Bevacizumab blocks the circulating vascu-
lar endothelial growth factor (VEGF), which serves as an
autocrine factor for the induction of neovascularization.
Also it acts as a survival factor for tumour cells, protecting
them from hypoxia, chemotherapy and radiotherapy. In
normal tissues its action is stabilisation of mature cells. It
has a beneficial effect in angiogenesis during wound heal-
ing [2].
Our patient had had a partial hepatectomy (trisectionec-
tomy) in the past and had also received oxaliplatin-based
chemotherapy, a drug recently found to cause hepatic
sinusoidal dilatation in hepatectomy specimens. To date
we have been unable to find any references on oxaliplatin
associated with any clinical signs or symptoms of SOS-
VOD[3,4]. Blue liver syndrome as a consequence of VOD
after the use of oxaliplatin has been reported by Bilchik et
PAS diastase and Van Gieson stains Figure 2
PAS diastase and Van Gieson stains. (a) PAS diastase stain showing Kupffer cell hyperplasia. (b) Van Gieson stain showing 
pericellular fibrosis adjacent to a terminal hepatic venule.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Medical Case Reports 2008, 2:227 http://www.jmedicalcasereports.com/content/2/1/227
Page 4 of 4
(page number not for citation purposes)
al. [5]. In our patient there was no evidence of blue liver
syndrome in the hepatectomy specimen after the use of
neoadjuvant oxaliplatin.
Potential explanations of the occurrence of the syndrome
are possible blockage of the normal repair mechanisms
induced by the VEGF, direct toxic action of the bevacizu-
mab to the hepatic sinusoids or idiosyncratic and/or
hypersensitivity reaction.
Conclusion
We need to be aware that bevacizumab can cause sinusoi-
dal obstruction syndrome (veno-occlusive disease) and
that the occurrence of ascites should not be attributed to
progressive disease without appropriate evaluation.
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